Tirzepatide, Zepbound, Mounjaro Compounding Ends
This is a Florida news story, published by CNBC, that relates primarily to Zepbound news.
Florida news
For more Florida news, you can click here:
more Florida newsZepbound news
For more Zepbound news, you can click here:
more Zepbound newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss drug Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest compounding pharmacy news, Pharmacy Compounding news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
diabetes drug MounjaroCNBC
•Health
Health
Zepbound copycats remain online despite FDA ban

79% Informative
Pharmacies were able to make copycat versions of Eli Lilly's Zepbound and Mounjaro while the drugs were in shortage.
The FDA declared the shortage over late last year .
Compounding is where pharmacies mix ingredients of a drug to create a specialized version for specific patients.
Online, it doesn't look like much has changed.
Mass compounding of semaglutide is the active ingredient in Novo Nordisk's Ozempic and Wegovy.
A Florida judge last year dismissed one of Lilly 's cases, saying the company was trying to enforce a law that only the FDA can.
The CEO of Mochi said she isn't worried about Lilly taking legal action against her providers.
VR Score
74
Informative language
69
Neutral language
78
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links
Small business owner?